We conducted a study to determine the prevalence and clinical patterns of footwear dermatitis, patch testing 50 patients with suspected footwear dermatitis and 30 controls with 22 allergens of a shoe series (Chemotechnique Diagnostics AB, Malmö, Sweden). The overall prevalence among contact dermatitis cases was 11.7%. The dorsa of the feet and toes were the commonest sites involved. 70% of patients showed sensitivity to footwear allergen(s), as opposed to 6.67% of controls. Potassium dichromate and colophony were the commonest sensitizers. Other sensitizers were the rubber accelerators 2-mercaptobenzothiazole (MBT) and diphenylguanidine (DPG) and a dye p-aminoazobenzene. Of the 23 patients patch tested with pieces or scrapings of footwear, only 3 showed positive reactions. We recommend that there should be primary and secondary footwear screening series to detect the responsible allergens, with the ultimate objective of providing correct nonallergenic footwear for our patients, with the help of manufacturers and research institutes.

Metastatic Crohn's disease (CD), a type of extraintestinal CD may present with gynecological manifestation which causes diagnostic dilemma and needs multidisciplinary approach. Vulvar lesions occur in very small number of cases with CD of which asymmetrical labial swelling and edema is the most common presentation. We report a case of hypertrophic exophytic variety of vulvar CD because of its rarity.

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a type of severe adverse cutaneous drug reaction characterized by fever, skin eruption, hematological abnormalities, and internal organ involvement. Although anticonvulsant drugs are mainly implicated in DRESS, newer anticonvulsants such as oxcarbazepine-induced definite cases of DRESS syndrome are rare and oxcarbazepine-induced DRESS syndrome presenting as exfoliative dermatitis is even rarer. We report a case of a 35-year-old male who developed DRESS syndrome presenting as exfoliative dermatitis after taking oxcarbazepine for 3 weeks.

No abstract

No abstract